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Cris dos Remedios , PhD; Michiel Dalinghaus, MD, PhD; Michelle Michels , MD, PhD; Folkert W. Asselbergs , MD, PhD;  
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BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease. While ≈50% of patients with 
HCM carry a sarcomere gene mutation (sarcomere mutation-positive, HCMSMP), the genetic background is unknown in 
the other half of the patients (sarcomere mutation-negative, HCMSMN). Genotype-specific differences have been reported 
in cardiac function. Moreover, HCMSMN patients have later disease onset and a better prognosis than HCMSMP patients. 
To define if genotype-specific derailments at the protein level may explain the heterogeneity in disease development, we 
performed a proteomic analysis in cardiac tissue from a clinically well-phenotyped HCM patient group.
METHODS: A proteomics screen was performed in cardiac tissue from 39 HCMSMP patients, 11HCMSMN patients, and 8 
nonfailing controls. Patients with HCM had obstructive cardiomyopathy with left ventricular outflow tract obstruction and 
diastolic dysfunction. A novel MYBPC32373insG mouse model was used to confirm functional relevance of our proteomic 
findings.
RESULTS: In all HCM patient samples, we found lower levels of metabolic pathway proteins and higher levels of extracellular 
matrix proteins. Levels of total and detyrosinated α-tubulin were markedly higher in HCMSMP than in HCMSMN and controls. 
Higher tubulin detyrosination was also found in 2 unrelated MYBPC3 mouse models and its inhibition with parthenolide 
normalized contraction and relaxation time of isolated cardiomyocytes.
CONCLUSIONS: Our findings indicate that microtubules and especially its detyrosination contribute to the pathomechanism 
of patients with HCMSMP. This is of clinical importance since it represents a potential treatment target to improve cardiac 
function in patients with HCMSMP, whereas a beneficial effect may be limited in patients with HCMSMN.
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Hypertrophic cardiomyopathy (HCM) is characterized by diastolic dysfunction and asymmetrical left ven-tricular (LV) hypertrophy, which leads to LV outflow 
tract obstruction in the majority of cases.1 Mutations in 
genes encoding sarcomere proteins cause HCM and 
are identified in more than half of the patients (sarco-
mere mutation-positive [HCMSMP]). The heterogene-
ity in genetic background of HCM is large with >1500 
identified HCM-causing mutations.2 Approximately 
80% of mutations are located in MYH7 and MYBPC3. 
Less frequent are mutations in TNNT2 and TNNI3.3,4 
Previous research in HCM mouse models and humans 
showed genotype-specific differences in cellular char-
acteristics and cardiac remodeling and function. Gene-
specific differences in cellular redox and mitochondrial 
function were reported in mice harboring a MYH7 or 
TNNT2 mutation.5 In accordance with studies in HCM 
mouse models, studies on patient myectomy samples 
reported gene-specific differences in the response to 
calcium, ADP (adenosine diphosphate), protein kinase A, 
and length-dependent activation (LDA) of myofilaments 
compared with nonfailing cardiomyocytes.6,7 Also, a com-
parison of 2 different patient-specific induced pluripotent 
stem cell-derived cardiomyocyte cell lines, carrying either 
a mutation in MYBPC3 or TPM1, showed differences in 
calcium handling and electrophysiological properties.8 
These in vitro studies are strengthened by clinical patient 
studies, which revealed a more severe decline in myocar-
dial efficiency in MYH7 than in MYBPC3 mutation car-
riers,9 accompanied by a different response to therapy.10 
Notably, there is also a large patient population in which 
a disease-causing mutation cannot be identified, the so-
called sarcomere mutation-negative patients (HCMSMN). 
While the cause of the disease in these patients is 
unknown, they present with the same clinical phenotype 
as HCMSMP patients albeit at older age.
3 Moreover, recent 
data from the SHaRe registry (the sarcomeric human 
cardiomyopathy registry) indicate that HCMSMP has a 
2-fold greater risk of adverse outcomes than HCMSMN.
11 
Whereas LV outflow tract obstruction can be invasively 
corrected by surgical myectomy, other symptoms can 
only be managed by pharmacological therapies, which 
do not halt or reverse cardiac disease.1 Knowledge about 
the cellular changes that cause cardiac dysfunction and 
hypertrophy in patients with HCM is needed to design 
new therapies.
The main goal of this study was to define HCM- and 
genotype-specific derailments at the protein level, which 
may explain the heterogeneity in cardiac characteristics 
and disease initiation and progression. Therefore, we 
used an unbiased proteomics approach in a large num-
ber of myectomy samples from a clinically well-charac-
terized HCM patient group with (HCMSMP) and without 
(HCMSMN) sarcomere mutations. We show that lower lev-
els of metabolic pathway proteins and higher levels of 
ECM (extracellular matrix) proteins are the most promi-
nent genotype-independent HCM-specific disease char-
acteristics at the time of myectomy. However, abundance 
and detyrosination of α-tubulin were significantly higher 
in HCMSMP than in nonfailing controls, with intermediate 
levels in HCMSMN. Recent studies in human heart failure 
identified a central role for detyrosinated microtubules in 
regulating cardiomyocyte function and demonstrated the 
functional benefit upon reversal of this modification.12,13 
Our study in a European HCM patient cohort and genetic 
HCM mouse models strengthens the concept that 










• This study shows that the most prominent derail-
ment at the protein level in cardiac tissue obtained 
during myectomy of patients with hypertrophic car-
diomyopathy (HCM) in an advanced disease stage 
is reduced levels of proteins involved in metabolic 
pathways. This is common for all genotypes.
• The study further demonstrates that increased lev-
els of detyrosinated tubulin are specific for sarco-
mere mutation-positive patients with HCM.
• The increase in tubulin detyrosination is resembled 
in a mouse model with the Dutch founder mutation 
MYBPC32373insG. Pharmacological inhibition of tubu-
lin detyrosination normalizes contractile function in 
isolated cardiomyocytes.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Recent and ongoing clinical trials investigate the 
therapeutic effect of targeting the energy metabo-
lism in patients with HCM, which is supported by 
our proteomic data showing metabolic derailment.
• Lowering tubulin detyrosination presents a poten-
tial novel treatment strategy that may improve con-
tractile function in patients with sarcomere mutation 
positive HCM. Since HCM is characterized by dia-
stolic dysfunction, enhancing cardiomyocyte relax-
ation by lowering detyrosination of microtubules is 
considered to be beneficial for patients with HCM.
• This study provides evidence that there is a need 
for genotype-specific treatment in HCM. Due to dif-
ferences in pathomechanism, not every therapeutic 
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targeting the microtubule network represents a thera-
peutic strategy to correct impaired function and extends 
it to HCM caused by sarcomere mutations.
METHODS
The proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner reposi-




Tissue of the interventricular septum (IVS) of 50 patients with 
HCM was obtained during myectomy surgery to relieve LV outflow 
tract obstruction or after heart transplantation (1 sample, HCM 
164). Samples of IVS from 8 healthy nonfailing donors (5 males, 
3 females; mean age 45.9±9.7 years) with no history of cardiac 
abnormalities was obtained from the Sydney Heart Bank (HREC 
Univ Sydney 2012/030) and served as controls. The parameters 
of all HCM and nonfailing individuals are summarized in Table I 
in the Data Supplement. In this table, we organized patients with 
HCM based on their genotype into 5 subgroups: patients with 
the Dutch MYBPC3 founder mutation (2373insG), where the 
truncating mutation resulted in MYBPC3 haploinsufficiency14; 
patients with MYBPC3 mutations other than the 2373insG muta-
tion of which 81.8% were truncating mutations as well; patients 
with MYH7 mutations; patients with mutations in less frequently 
affected sarcomere genes (TNNT2, TNNI3, and MYL2); and 
HCMSMN patients. In line with studies in other cohorts,
15 almost 
all mutations in MYBPC3 were truncating mutations, whereas 
mutations in other sarcomeric proteins were missense except the 
truncating mutation c.814C>T in TNNT2.
Proteomics Analysis
Tissue Homogenization
Pulverized frozen tissue was homogenized in 40 μL/mg tissue 
1× reducing sample buffer (106 mmol/L Tris-HCl, 141 mmol/L 
Tris-base, 2% lithium dodecyl sulfate, 10% glycerol, 0.51 mmol/L 
ethylenediaminetetraacetic acid, 0.22 mmol/L SERVA Blue 
G250, 0.18 mmol/L Phenol Red, and 100 mmol/L dithiothreitol) 
using a glass tissue grinder. Proteins were denatured by heating 
to 99 °C for 5 minutes, after which samples were sonicated and 
heated again. Debris was removed by centrifugation at maximum 
speed for 10 minutes in a microcentrifuge (Sigma, 1-15K).
Protein Fractionation
Proteins were separated using 1D SDS-PAGE. Samples from 
each group were loaded alternating on the gels to avoid bias. 
Equal volumes of sample (30 μL protein homogenate per 
sample, containing ≈20–30 μg of protein) were loaded on 
a precast 4% to 12% NuPAGE Novex Bis-Tris 1.5 mm mini 
gel (Invitrogen). Electrophoresis was performed at 200 V in 
NuPAGE MES SDS running buffer until the dye front reached 
the bottom of the gel. Gels were fixed in a solution of 50% 
ethanol and 3% phosphoric acid and stained with 0.1% coo-
massie brilliant blue G-250 solution (containing 34% methanol, 
3% phosphoric acid, and 15% ammonium sulfate). Images of 
all gels are provided in Figure I in the Data Supplement.
In-Gel Digestion and Nano-LC-MS/MS
Each gel lane was cut into 5 pieces, and in-gel digestion was 
performed as described previously.16 Samples were measured 
by  liquid chromatography-mass spectrometry (LC-MS) per gel 
band starting at the high molecular weight fraction for all sam-
ples, before continuing with the next gel band until the last (low 
molecular weight fraction) band. Injections alternated between all 
different group samples to minimize experimental bias between 
groups. Analysis of the experiment was performed as described in 
Piersma et al.17 Peptides were separated using an Ultimate 3000 
Nano LC-MS/MS system (Dionex LC-Packings, Amsterdam, The 
Netherlands) equipped with a 40 cm × 75 μm ID fused-silica col-
umn custom packed with 1.9 μm,120 Å ReproSil Pur C18 aqua 
(Dr Maisch GMBH, Ammerbuch-Entringen, Germany). Eluting 
peptides were ionized at a potential of +2 kV into a Q Exactive 
mass spectrometer (Thermo Fisher, Bremen, Germany). MS/MS 
spectra were acquired at resolution 17 500 (at m/z 200) in the 
orbitrap using an AGC target value of 1×106 charges, a maxIT 
of 60 ms, and an underfill ratio of 0.1%. Dynamic exclusion was 
applied with a repeat count of 1 and an exclusion time of 30 s 
(additional details to in-gel-digestion and nano-LC-MS/MS are 
provided in the Data Supplement).
Data Analysis
MS/MS spectra were searched against a Uniprot human ref-
erence proteome FASTA file (Swissprot_2017_03_human_
canonical_and_isoform.fasta, 42161 entries) using MaxQuant 
version 1.5.4.1 (details to search settings are provided in the 
Data Supplement). The mass spectrometry proteomics data 
are provided in Table V in the Data Supplement, and the raw 
data have been deposited to the ProteomeXchange Consortium 
via the PRIDE18 partner repository with the data set identifier 
PXD012467. Beta-binominal statistics were used to assess 
differential protein expression between groups, after normaliza-
tion on the sum of the counts for each sample.19 Proteins with 
a P value below 0.05 were considered significantly differentially 
expressed. Proteins which were present in <25% of the samples 
or had an average normalized count of <1.4 were excluded from 
further functional analysis. Principal component analysis was 
performed in R. Therefore, quantile normalization and log2 trans-
formation were performed on the normalized counts. The 95th 
percentile was taken, the data median centered, and the principal 
components calculated. Hierarchical clustering was performed 
after a statistical multigroup comparison. Proteins with a raw 
P<0.05 were selected for the pathway analysis. Protein networks 
were generated using the STRING database (Search Tool for 
the Retrieval of Interacting Genes/Proteins) and visualized with 
Cytoscape software.20 Protein interaction networks were gener-
ated with ClusterONE and gene ontology (GO) analysis was per-
formed using the BiNGO application in cytoscape.21,22 Heatmaps 
for a specific GOs were created with ToppGene Suite23 and 
Graphpad Prism v7 software. Venn diagrams were created with 
InteractiVenn tool24 and the layout modified if needed.
Animal Experiments
The MYBPC32373insG mouse model was engineered using 
CRISPR/Cas9 (clustered regularly interspaced short palin-
dromic repeats/CRISPR associated protein 9, details are pro-
vided in the Data Supplement). Echocardiographic phenotyping 
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MYBPC32373insG mice (3 females and 4 males) and 8 wild-type 
(WT) littermates (3 females and 5 males). The age of the mice 
ranged from 20 to 28 weeks. Group size of 7 was determined 
by a power calculation to achieve a power of 0.8 and an α of 
0.05 and to detect an effect size of 20% in echocardiography.
The MYBPC3772G>A mice were developed previously
25 and 
maintained on a blackswiss genetic background. Western blot 
analysis was performed of the cytosolic fraction of LV tissue in 
6 homozygous MYBPC3772G>A mice (2 females and 4 males) 
and 6 WT littermates (2 females and 4 males). The age of 
these mice was 55 to 59 weeks.
Intact Cardiomyocyte Isolation and Measurements
Intact adult cardiomyocytes were isolated from 4 WT and 
6 homozygous MYBPC32373insG mice as described previ-
ously.26 Cells were suspended in plating medium composed 
of medium 199 (Lonza), 1% penicillin/streptomycin, and 5% 
bovine serum and plated on a laminin-coated dish (10 μg/mL, 
Sigma-Aldrich). The cells were incubated for 1 hour at 37 °C 
in humidified air with 5% CO2 to let them attach to the coated 
dish. Afterwards, nonattached cells were removed by washing 
cells with preheated culture medium (medium 199 [Lonza], 1% 
penicillin/streptomycin, 1×ITS supplement [Sigma-Aldrich], 
and 0.5 μmol/L cytochalasin D [Life technologies]). Cells were 
incubated with dimethyl sulfoxide (0.1% v/v) or 10 μmol/L par-
thenolide (Sigma) for 2 hours. Contractility measurements were 
performed in tyrode solution (HEPES (4-(2-hydroxyethyl)-1-pi-
perazineethanesulfonic acid) 10 mmol/L, NaCl 133.5 mmol/L, 
KCl 5 mmol/L, NaH2PO4 1.2 mmol/L, MgSO4 1.2 mmol/L, 
glucose 11.1 mmol/L, sodium pyruvate 5 mmol/L; pH 7.4 at 
37 °C) at 37 °C using the MultiCell system (CytoCypher, the 
Netherlands). The dish was field-stimulated at 2 Hz, 25 V, and 
a 4 ms pulse duration. Changes in sarcomere length were 
recorded with a high-speed camera and Ionoptix software 
(Ionoptix, Westwood, MA). The contractility profiles were ana-
lyzed with the automated batch analysis software CytoSolver 
(CytoCypher, Amsterdam, NL). An R2 for peak and recovery fit 
>0.95 was selected as inclusion criteria for contraction data.
For protein analysis, cells were incubated with dimethyl 
sulfoxide (0.1% v/v) or 10 μmol/L parthenolide (Sigma) for 2 
hours, washed with PBS, and directly lysed in loading buffer.
Study Approval
The study protocol for the human tissue samples was approved 
by the local medical ethics review committees, and written 
informed consent was obtained from each patient before surgery.
Animal experiments were performed in accordance with 
the Guide for the Animal Care and Use Committee of the VU 
University Medical Center and with approval of the Animal 
Care Committee of the VU University Medical Center (CCD-
number AVD114002016700) and conform the guidelines 
from Directive 2010/63/EU of the European Parliament on 
the protection of animals used for scientific purposes.
Extended methods section in the Data Supplement.
RESULTS
No Major Genotype-Specific Protein Changes
We performed an unbiased proteomics approach to com-
pare the protein expression profile of 50 IVS samples 
from patients with HCM at the time of myectomy with 8 
nonfailingIVS samples (Table, Table I in the Data Supple-
ment; patient characteristics). Patient characteristics are 
shown in the Table. Echochardiographic parameters were 
assessed as described previously.27 All patients with HCM 
had obstructive HCM and showed impaired diastolic func-
tion evident from increased LV filling pressure indicated by 
an E/e′ ratio >15 and atrial dilation indicated by increased 
left atrial diameter compared with reference values.28,29 IVS 
thickness was higher in HCMSMP compared with HCMSMN. 
We identified 3811 proteins of which we included 2127 
into our analysis after applying our inclusion criteria of an 
average normalized count of >1.4 and the protein being 
detected in >25% of samples. This filtered out low-level 
proteins that could not be reliably quantified. Samples were 
grouped based on their genotype and protein expression 
changes were analyzed in different group-wise compari-
sons. Table II in the Data Supplement lists all group-wise 
comparisons and the corresponding number of significantly 
deregulated proteins that contributed to the subsequent 
cluster and GO analysis. An unbiased principal component 
analysis of the protein expression data revealed separate 
clustering of the nonfailingIVS and HCM samples, indicat-
ing different protein expression profiles between controls 
and patients (Figure 1A). Supervised hierarchical clustering 
of a multigroup comparison revealed separate clusters for 
nonfailingIVS and HCM samples (Figure 1B). However, in 
both analyses, the HCM samples did not cluster according 
to their genotypes, indicating that the protein profile at the 
time of myectomy surgery is relatively homogeneous with 
differences between genotypes that are not sufficiently 
large to distinguish them with cluster analysis. Sample 
HCM 83 did not cluster with any of the other HCM or non-
failingIVS samples and turned out to have a very high serum 
albumin content. This implicated contamination with blood 
and, therefore, we excluded this sample from all further 
analyses. Sample HCM 164 also showed a unique protein 
expression pattern. It may reflect the infant proteome due 
to the young age (2 months), or the very severe disease 
stage since this is the only sample obtained from a heart 
transplantation. Since the variation in this sample is due to 
a biological reason, we did not exclude it.
To validate our experimental approach, we checked 
the expression of proteins involved in pathways that 
are known to be altered in HCM (Figure II and Table III 
in the Data Supplement). Fibrosis, characterized by an 
increase in ECM components, is a well-established fea-
ture of HCM as shown by data from myectomy biopsies 
and cardiac magnetic resonance imaging of patients.27,30 
In line with the presence of fibrosis in patients, we found 
increased levels of fibronectin, thrombospondin 4, and 
periostin (Figures IIA through IIC in the Data Supple-
ment). Since hypertrophy is a morphological hallmark of 
HCM, we checked FHL2 (four and a half LIM domains 
protein 2) expression as a negative regulator of hyper-
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FHL2 protein expression was observed (Figure IID in 
the Data Supplement). The hypertrophic phenotype was 
also evident from reduced (alpha-myosin heavy chain) α-
MHC encoded by MYH6 and increased CSRP3 (cysteine 
and glycine rich protein 3) expression in HCM samples 
(Figure IIE and IIF in the Data Supplement).32,33 Finally, 
MYBPC3 (cardiac myosin-binding protein C) haploin-
sufficiency was confirmed in samples with a mutation 
in MYBPC3 irrespective of whether the mutation is a 
truncation or missense mutation (Figure IIG and IIH and 
Table IV in the Data Supplement).14,34
Additionally, we performed RNA sequencing in a sub-
set of samples. Similar to the proteomics data, the prin-
cipal component analysis plot of the RNA data did not 
show clustering based on genotype (Figure IIIA in the 
Data Supplement). The MA-plot depicts all genes with 
the differentially expressed genes in red (Figure IIIB in 
the Data Supplement).Gene set enrichment analysis of 
the proteomics and transcriptomics data revealed a sig-
nificant correlation of upregulated proteins with genes 
that showed higher expression levels in HCM compared 
with nonfailingIVS (false discovery rate (FDR)<0.001), 
whereas less expressed proteins are positively corre-
lated with genes that showed lower expression levels 
in HCM (FDR=0.008). This observation suggested that 
protein expression changes were well correlated with the 
mRNA expression changes between HCM and nonfailin-
gIVS (Figure IIIC and IIID in the Data Supplement).
HCM-Specific Protein Changes
To identify HCM disease-specific protein expression 
patterns at the time of myectomy, we grouped all HCM 
samples and compared them to nonfailingIVS. We identi-
fied clusters of interacting proteins for higher and lower 
expressed proteins separately.
Analysis of all significantly lower expressed proteins 
of all HCM compared with nonfailingIVS uncovered the 
highest enrichment in oxidative phosphorylation, gener-
ation of precursor metabolites and energy, NAD meta-
bolic process, translation, fatty acid catabolic process, 
regulated exocytosis, and neutrophil degranulation 
(Figure 2A, more extensive list in Figure IV in the Data 
Supplement). This shows that the major changes in tis-
sue of patients with HCM are in metabolic pathways 
related to energy metabolism including both glucose 
and fatty acid metabolism. We selected all significantly 
lower expressed proteins annotated to the pathways 
Table. Clinical Characteristics of the HCMSMP and HCMSMN Patient Group
 HCMSMP (n=38) HCMSMN (n=11) P value
Sex, male 65.8% (25) 63.6% (7) >0.9999
Age at myectomy, y 46.2±17.4 53.6±13.9 0.2084
Dimensions, mm
 IVS 21.0 [18.8–23.3] 16.0 [15.0–18.0] <0.0001*
 LAD 46.0±6.5 48.1±5.4 0.3861
 EDD 42.5±5.2 44.3±6.4 0.4466
 ESD 21.7±5.0 26.0±2.8 0.2595
Diastolic parameters
 E/A ratio 1.16 [0.81–1.54] 0.92 [0.67–1.15] 0.1795
 E/e′ ratio 16.2 [13.1–20.1] 21.7 [16.0–33.4] 0.0226*
 TR velocity, cm/s 2.3±0.5 NA  
Stadium of diastolic dysfunction
 1 46.9% (15) 40.0% (4) >0.9999
 2 31.3% (10) 40.0% (4) 0.7071
 3 21.9% (7) 20.0% (2) >0.9999
Systolic parameters
 FS (%) 47.4±11.7 47.5±0.7 0.9942
 LVOTg, mm Hg 54.9±31.9 91.7±40.9 0.0034*
Medication
 β-blocker 79.5% (31) 63.6% (7) 0.4240
 calcium channel blocker 33.3% (13) 45.5% (5) 0.4945
 Statins 12.8% (5) 18.2% (2) 0.6407
Displayed are the mean±SD or the median with interquartile range when appropriate. EDD indicates end-diastolic diam-
eter; ESD, end-systolic diameter; FS, fractional shortening; HCM, hypertrophic cardiomyopathy; IVS, interventricular septum; 
LAD, left atrial diameter; LVOTg, left ventricular outflow tract gradient; SMN, sarcomere mutation-negative; SMP, sarcomere 
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Figure 1. Clustering of proteome of controls and patient samples.
A, Principal component (PC) analysis of the filtered protein expression data reveals separate clustering of the nonfailing interventricular 
septum (NFIVS) samples (n=8) and the hypertrophic cardiomyopathy (HCM) samples (n=50) showing that the overall protein expression profile 
between NFIVS and HCM samples differs. HCM samples did not form separate clusters based on genotypes, indicating that genotype does not 
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and created a heatmap displaying the log2-fold change 
for a detailed visualization of protein changes in the 
pathway. We included RNA expression data of the cor-
responding genes to check if the protein changes coin-
cide with changes at the RNA level. Strikingly, most of 
these proteins are not changed on RNA level (Figure V 
in the Data Supplement).
The top clusters of the higher expressed proteins are 
associated with the GO terms ECM organization, actin 
filament-based process, myofibril assembly, muscle con-
traction, post-translational protein modification, protein 
folding, and microtubule cytoskeleton organization (Fig-
ure 2B, more extensive list in Figure VI in the Data Sup-
plement). The biggest cluster of more abundant proteins 
is ECM organization representing different collagens that 
are components of fibrotic tissue. Interestingly, many of 
these genes showed unaltered RNA levels compared with 
nonfailingIVS. The same was observed for the other top 
clusters of higher expressed proteins, namely actin fila-
ment-based process, myofibril assembly, and muscle con-
traction, where RNA levels were unaltered or even lower 
than in nonfailingIVS (Figure VII in the Data Supplement).
Since HCM at the time of myectomy is characterized by 
pronounced hypertrophy of the myocardium, we expected 
a protein cluster related to hypertrophy among the signifi-
cantly increased proteins. Surprisingly, we did not find this. 
This could be because the myocardium is not in a state of 
active hypertrophic growth at the time of sample collection, 
or because we did not detect low abundant hypertrophy 
promoting signaling proteins. It is also known that several 
signaling proteins are regulated by post-translational modi-
fications rather than by abundance on which our proteomics 
screen was based. Western blot analysis of the expres-
sion and phosphorylation of AKT (protein kinase B) and 
ERK (extracellular signal-regulated kinase), 2 well-known 
inducers of hypertrophy,35,36 showed higher AKT and ERK 
phosphorylation in all HCM samples, indicating activation of 
hypertrophic signaling (Figure VIII in the Data Supplement).
Subsequently, we repeated the cluster and GO 
analysis restricted to proteins that are higher and lower 
expressed if all 5 genotype HCM groups are compared 
individually to nonfailingIVS to extract the most consistent 
and robust changes. Venn diagrams (Figures IX and X in 
the Data Supplement) were made to identify overlapping 
protein changes (76 higher and 92 lower expressed), 
which were subsequently used as analysis input.
The results confirmed the findings from the initial 
analysis showing that the major HCM-specific protein 
changes include reduced metabolism, increased ECM 
remodeling, and pathways, including muscle-related 
processes.
Specific Changes for HCMSMP and HCMSMN
To study the pathways that are characteristic for HCMSMP 
or HCMSMN and might explain sarcomere mutation-spe-
cific changes in cardiac function, we created a Venn 
diagram of significantly different proteins in HCMSMP 
and HCMSMN compared with nonfailingIVS. The Venn dia-
grams (Figure 3 and Figure XI in the Data Supplement) 
illustrate that the majority of significantly different pro-
teins are similar in HCMSMP and HCMSMN (191 lower and 
121 higher expressed proteins). However, a substantial 
number of proteins is only changed in either HCMSMP or 
HCMSMN, when compared with nonfailingIVS.
The 130 proteins that are specifically less abundant 
in HCMSMP overlap to a large degree with the biologi-
cal processes of the 194 proteins that are significantly 
less abundant in both HCMSMP and HCMSMN when com-
pared with nonfailingIVS (Figure XII in the Data Supple-
ment). Analysis of the 62 proteins that are specifically 
less expressed in HCMSMN results in clusters related to 
stress granule assembly, translational initiation, and pro-
tein folding (Figure XI in the Data Supplement).
The majority of the shared higher expressed proteins 
involve ECM organization (Figure XIII in the Data Supple-
ment). GO analysis of the 68 proteins that are specifi-
cally more abundant in HCMSMP identified among others 
a protein clusters related to microtubule cytoskeleton 
organization (Figure 3).
This cluster representing tubulin subunits is solely 
more abundant in HCMSMP when compared with non-
failingIVS and is also among the functional protein cluster 
of proteins that are significantly upregulated in HCMSMP 
when directly compared with HCMSMN (Figure XIV in the 
Data Supplement). Since the tubulin network is highly 
regulated by post-translational modifications, we deter-
mined the levels of total α-tubulin, tyrosinated, and dety-
rosinated tubulin by Western blot (Figure 4, Figure XVA 
in the Data Supplement). In line with the proteomics data, 
we found an increase in total α-tubulin which is more 
prominent in HCMSMP than in HCMSMN (Figure 4A). We 
validated this with another primary antibody and obtained 
very comparable results (Figure XVA in the Data Supple-
ment). A post-translational modification of tubulin that 
leads to increased stiffness of cardiomyocytes is detyros-
ination of α-tubulin.12 We found markedly elevated dety-
rosinated tubulin only in HCMSMP samples (Figure 4C), 
while levels of tyrosinated tubulin were slightly increased 
in both HCMSMP and HCMSMN (Figure 4B). Within the 
HCMSMP group, levels of α-tubulin tend to be highest in 
the MYBPC3other group and lowest in the MYH7 group, 
whereas desmin levels tend to be highest in MYH7. 
Figure 1 Continued. (HCMSMN) samples do not show major differences at the overall protein expression profile as they cluster together. B, 
Hierarchical clustering of a multigroup comparison of all proteins that are differently expressed at P<0.05 when comparing all HCM (HCMall) 
with NFIVS. Hierarchical clustering of all significantly different proteins between HCMall and NFIVS shows that the NFIVS samples cluster together 
and are most different from the HCM samples. Also among this selection of proteins, the HCM samples do not cluster based on genotype or 
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Figure 2. Hypertrophic cardiomyopathy (HCM)-specific changes in biological processes.
Protein interaction cluster of significantly different proteins between all HCM (HCMall) and nonfailing interventricular septum (NFIVS) were 
identified and are displayed with the most significant corresponding gene ontology (GO) term. A, Top 10 downregulated protein interaction 
cluster based on cluster size with the most significant biological process related to this cluster. B, Top 10 upregulated protein interaction 
cluster based on cluster size with the most significant biological process related to this cluster. The color gradient from light to dark indicates 
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Levels of tyrosinated and detyrosinated tubulin do not 
show any genotype-specific differences. Levels of tyros-
inated and detyrosinated tubulin normalized to total α-
tubulin are depicted in Figure XVB and XVC in the Data 
Supplement. Our data show that high levels of tubulin 
in HCMSMP represent mostly the detyrosinated form. We 
also determined desmin protein levels by Western blot 
since this protein is associated with microtubules in car-
diomyocytes. Accordingly, desmin levels were elevated in 
HCM with the largest increase in HCMSMP (Figure 4D).
Inhibition of Tubulin Detyrosination Corrects 
Cardiomyocyte Dysfunction in MYBPC32373insG 
Mice
Based on previous studies in human heart failure,13 our 
data in human myectomy samples indicate that micro-
tubules may represent a treatment target to correct 
cardiac dysfunction in HCM. To provide proof for a role 
of tubulin in modulating cardiomyocyte function in HCM 
caused by a sarcomere gene mutation, we generated a 
HCM knockin mouse model of the Dutch founder muta-
tion c.2373insG in MYBPC3 (Figure XVIA and XVIB in 
the Data Supplement). This mutation introduces a new 
splice donor site in exon 25 leading to a frameshift and 
premature stop codon resulting in an expected truncated 
protein of 95 kDa.37 As no truncated protein is found in 
patients with HCM carrying this mutation at the hetero-
zygous state,14 degradation of mutant mRNA and protein 
is likely. Accordingly, Western blot analysis did not reveal 
any truncated MYBPC3 protein in homozygous MYBP-
C32373insG mice (Figure XVIC in the Data Supplement).
Levels of total and tyrosinated α-tubulin did not dif-
fer between the groups, whereas the detyrosinated 
tubulin and desmin levels were markedly higher in MYB-
PC32373insG than in WT mice (Figure 5A -5D, loading 
Figure 3. Differences in upregulated proteins between patients with hypertrophic cardiomyopathy sarcomere mutation-positive 
(HCMSMP) and sarcomere mutation-negative (HCMSMN).
Protein interaction cluster of proteins that are only significantly upregulated for the HCMSMP vs nonfailing interventricular septum (NFIVS) or the 
HCMSMN vs NFIVS comparison were identified and are displayed with the most significant corresponding gene ontology (GO) term. The top 5 
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control to Figure 5A shown in Figure XVD in the Data 
Supplement). To evaluate whether these findings were 
specific to this model, we assessed the levels of total and 
detyrosinated tubulin in a second HCM mouse model 
carrying a different MYBPC3 mutation.25 Homozygous 
MYBPC3772G>A mice showed a strong accumulation of α-
tubulin and no difference in tyrosinated tubulin compared 
with their WT littermates. In addition, a trend to higher 
Figure 4. Tubulin expression and post-translational modifications in patients with hypertrophic cardiomyopathy (HCM).
Protein levels of α-tubulin (A), its tyrosinated (B) and detyrosinated forms (C) and desmin (D), all normalized to GAPDH, in tissue of patients 
with HCM. Kruskal-Wallis test with Dunn's multiple comparisons test, ****P<0.0001, ***P=0.0003 in (B), ***P=0.0009 in (D), **P=0.0074, 
*P=0.0437 in (A), *P=0.0499 in (B) and *P=0.0357 in (D). Average of the control group is set to 1. n(nonfailing interventricular septum 





 http://ahajournals.org by on February 11, 2021
Schuldt et al Detyrosinated Tubulin as Treatment Target in HCM
Circ Heart Fail. 2021;14:e007022. DOI: 10.1161/CIRCHEARTFAILURE.120.007022 January 2021 49
levels of detyrosinated tubulin was observed (Figure 5E 
through 5G). Overall, these mouse models consistently 
show tubulin changes in cardiomyopathy caused by 
MYBPC3 gene mutations.
MYBPC32373insG mice had a severe cardiac pheno-
type characterized by higher ventricular weight to body 
weight ratio, increased LV anterior wall diameter and IVS 
thickness, lower ejection fraction, increased LV internal 
diameter and longer isovolumetric relaxation time than 
WT mice (Figure 6A through 6F). Single cardiomyocytes 
from MYBPC32373insG hearts showed contractile deficits 
compared with WT as shown by an increase in time to 
peak of contraction and an impaired relaxation shown 
by an increase in time to baseline (Figure 6G and 6H). 
Inhibition of detyrosination by treatment with parthe-
nolide reduced levels of detyrosinated tubulin by 36% 
(Figure 6J) and normalized the contraction and relax-
ation times in MYBPC32373insG mice to baseline WT levels 
(Figure 6G and 6H), whereas it had no effect on calcium 
release and reuptake time in MYBPC32373insG mice (Fig-
ure XVIIA and XVIIB in the Data Supplement), indicating 
a direct effect on myofilament function.
DISCUSSION
In this study, we compared the protein profile of car-
diac tissue from patients with HCM with different 
disease-causing gene mutations to identify common 
HCM disease changes as well as genotype-specific 
protein changes at the time of myectomy. The major-
ity of detected protein changes were common for all 
HCM samples and independent of the underlying gene 
mutation. Our approach revealed different protein pro-
files in the presence or absence of a sarcomere gene 
mutation. While hypertrophic remodeling in HCMSMP 
is characterized by an increase in the levels of pro-
teins involved in microtubule cytoskeleton organiza-
tion, HCMSMN samples show reduced levels of proteins 
involved in protein translation.
Deregulated Energy Metabolism Proteome
Our analysis revealed that the majority of deregulated 
proteins are related to energy metabolism and show 
a consistent lower expression of proteins involved in 
Figure 5. Tubulin composition in MYBPC32373insG and MYBPC3772G>A mouse models.
Quantification and representative Western blot images of (A) α-tubulin, (B) tyrosinated tubulin, (C) detyrosinated tubulin, and (D) desmin 
in MYBPC32373insG mice and (E) α-tubulin, (F) tyrosinated tubulin and (G) detyrosinated tubulin in MYBPC3772G>A mice, respectively. A is 
normalized to total protein stain (TPS, image provided in Figure XVD in the Data Supplement). B–G are normalized to GAPDH. Lanes in A 
were run on the same gel but were noncontiguous. n(wild type [WT]/MYBPC32373insG/ MYBPC3 772G>A)=6/6 (4 females, 2 males/3 females, 3 males 
of 20–27 wk for MYBPC32373insG and the corresponding WT; 2 females, 4 males for of 55–59 wk for MYBPC3772G>A and the corresponding 
WT) for (A, C, and E–G), 6/5 (4 females, 2 males/3 females, 2 males; 20–27 wk) for (B) and 5/5 (3 females, 2 males/2 females, 3 males; 




 http://ahajournals.org by on February 11, 2021
Schuldt et al Detyrosinated Tubulin as Treatment Target in HCM
Circ Heart Fail. 2021;14:e007022. DOI: 10.1161/CIRCHEARTFAILURE.120.007022 January 2021 50
Figure 6. Morphometric and phenotypic analysis of MYBPC32373insG mice and contractile function of isolated MYBPC32373insG 
cardiomyocytes upon inhibition of tubulin detyrosination.
Quantification of the hypertrophy parameters (A) ventricle weight (VW)/body weight (BW) ratio and (B) anterior wall thickness in diastole 
(LWADd) and (C) interventricular septum thickness in diastole (IVSd) measured by echocardiography. D and E show parameters of systolic 
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oxidative phosphorylation, glycolysis, and fatty acid oxi-
dation. Especially subunits of mitochondrial respiratory 
chain complex I, that are part of cluster 1 in Figure 2A, 
are consistently lower expressed. This is in line with 
another recent proteomics study of HCM tissue samples 
in which reduced levels of energy metabolism proteins 
was one of the main findings.38 It also matches observa-
tions of energy deficiency in animal models39 and human 
studies.40,41 Energy deficiency has been proposed as the 
primary mutation-induced pathomechanism leading to 
compensatory hypertrophy,42 which is supported by the 
fact that even asymptomatic mutation carriers without 
hypertrophy display reduced cardiac energetic status.9,41 
The reduced cardiac efficiency was larger in MYH7 
mutation carriers compared with MYBPC3 mutation 
carriers pointing towards genotype-specific functional 
differences.9 Our proteomic analyses did not show gene-
dependent differences in proteins involved in cardiac 
energy metabolism. This indicates that the deregulated 
energy metabolism proteome is a secondary conse-
quence due to cellular stress that is similar in patients 
with advanced HCM.
Protein Homeostasis Differs Between HCMSMP 
and HCMSMN
Interestingly, proteins involved in protein translation 
are less abundant, particularly in HCMSMN patient 
tissue when compared with nonfailingIVS, implying 
that the protein translation system is either more 
impaired or differently regulated in HCMSMN. Among 
the more abundant proteins, we observed a protein 
cluster related to protein folding. Protein-folding pro-
teins (chaperones) are needed for correct folding of 
de novo synthesized proteins as well as for refolding 
of misfolded mutant or damaged proteins. Since our 
data show downregulation of protein translation, it is 
unlikely that protein-folding proteins are upregulated 
for folding of newly synthesized proteins. Instead, 
we speculate that their expression is upregulated to 
repair or remove misfolded (mutant) proteins.43 This 
is in line with recent data describing an upregula-
tion of protein-folding proteins specifically in HCMSMP 
samples.44 Protein-folding proteins represent potential 
treatment targets since boosting their expression has 
already shown beneficial effects in animal models of 
other cardiac diseases and in cardiomyopathies.45–47
Impact of Increased Tubulin Network on 
Cardiomyocyte Function in HCM
A striking observation was the specific upregulation of 
microtubule subunits and post-translational modifica-
tion detyrosination in HCMSMP compared with HCMSMN, 
when comparing both to nonfailingIVS. Previous studies 
indicated important regulatory roles of microtubules in 
cardiomyocyte function.48 Recent reports showed that 
the translation of the sarcomere proteins is localized to 
the myofilaments which points to a role of microtubules 
in the transportation of mRNA to the myofilament.49,50 
Increased expression of tubulin subunits strengthens the 
microtubule network and facilitates the transportation 
of mRNAs to the sarcomere and concomitant increas-
ing cardiomyocyte stability. In addition to tubulins, des-
min protein level was significantly higher in HCMSMP than 
in HCMSMN. In the healthy heart, desmin is localized at 
the Z-discs forming a striated pattern and playing a cen-
tral role in cardiomyocyte mechanical stability.51 Overall, 
these protein changes suggest a compensatory mecha-
nism of the cell to ensure sarcomere stability in the pres-
ence of a sarcomere gene mutation.
Furthermore, microtubules and their post-translational 
modifications play an important role in cardiomyocyte 
mechanics, especially in regulating cardiomyocyte stiff-
ness.52,53 Detyrosinated tubulin stabilizes microtubules 
by inhibiting disassembly54 and can anchor microtubules 
to the Z-discs of the sarcomere, most likely via desmin, 
and enhance stability and stiffness of the myofilaments 
and the microtubular network.52 The TUBA4A transcript 
is directly synthesized in it is detyrosinated form and an 
upregulation could at least partly explain the increase in 
detyrosinated tubulin. In our RNA sequencing data, the 
TUBA4A transcript is, however, significantly downregu-
lated when comparing HCM with nonfailingIVS, and it is 
not differentially expressed in the direct comparison of 
HCMSMP and HCMSMN.
Tubulin detyrosination is enzymatically regulated by 
the tubulin tyrosine ligase and tubulin carboxypeptidases 
that have detyrosinating activity and also the TUBA4A 
transcript can undergo these reactions.55 Recently, vaso-
hibins have been identified as the first tubulin detyros-
inating enzymes56,57 and act in complex with SVBP (small 
vasohibin-binding protein). In accordance with findings 
by Robison et al12 in explanted hearts of heart failure 
and cardiomyopathy patients,12 we observed a specific 
upregulation of tubulins and enhanced detyrosination 
Figure 6 Continued. isovolumetric relaxation time (IVRT). n(wild type [WT]/MYBPC32373insG)=9/9 (4 females, 5 males; 20–27 wk) for (A) 
and 8/7 (3 females, 5 resp. 4 males; 25–27 wk) for (B–F), unpaired 2-tailed t test, ****P<0.0001, ***P=0.0001. G displays the effect of 
tubulin detyrosination inhibition by parthenolide (PTL) on the contractile parameter time to peak 70% and (H) on the diastolic parameter 
time to baseline 70%. The dotted line visualizes the WT baseline level. I shows example force transients for each condition of the single-cell 
measurements. For (G and H) N(WT mice)=4 (2 females and 2 males, 13–33 wk) with total n(cells dimethyl sulfoxide [DMSO]/PTL)=191/99 
and N(MYBPC32373insG mice)=6 (2 females and 4 males, 13–35 wk) with total n(cells DMSO/PTL)=169/123. G and H were analyzed by 2-way 
ANOVA, **P<0.01, ****P<0.0001. J, Levels of detyrosinated tubulin normalized to GAPDH in isolated MYBPC32373insG cardiomyocytes upon 
inhibition of tubulin detyrosination by PTL. Every PTL treated sample was normalized to the DMSO control condition from the same animal. 
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in our genetically well-characterized HCM myectomy 
samples. Notably, we found the increase in tubulin dety-
rosination specific for HCMSMP samples. Although levels 
of detyrosinated tubulin are equal between HCMSMP and 
HCMSMN when normalized to total levels of α-tubulin, the 
absolute levels of α-tubulin and detyrosinated tubulin are 
much higher in HCMSMP and thereby have a much greater 
impact on contractile function in these patients. Chen et 
al13 have already demonstrated the reversibility of tubulin 
detyrosination in isolated cardiomyocytes from explanted 
HCM hearts associated with an improvement of con-
tractile function.58 Here, we performed proof-of-concept 
studies in HCM mouse models to define the impact of 
tubulin detyrosination in the presence of a sarcomere 
mutation. Homozygous MYBPC32373insG mice replicated 
the tubulin detyrosination without an increase in total 
α-tubulin levels, whereas homozygous MYBPC3772G>A 
mice display an increase in total α-tubulin with a trend 
to increased tubulin detyrosination. Considering the age 
difference of the mice with the MYBPC3772G>A mice being 
much older than the MYBPC32373insG mice at the time of 
analysis, we speculate that the increase in tubulin dety-
rosination is an early disease change together with an 
increase in desmin protein levels, which is followed by 
an increase of total α-tubulin during disease progres-
sion and ageing. In MYBPC32373insG mice, we showed that 
the increase in tubulin detyrosination is accompanied by 
reduced contraction and relaxation kinetics in isolated 
intact cardiomyocytes. Inhibition of tubulin detyrosina-
tion by parthenolide restored contraction and relaxation 
kinetics to WT levels in MYBPC32373insG cardiomyocytes. 
The used concentration of parthenolide has already been 
proven to be sufficient to reduce detyrosination of tubu-
lin12,59 and Chen et al13 and Robison et al12 have demon-
strated that the parthenolide-induced effects on kinetics 
of contraction are the same as obtained by overexpres-
sion of tubulin tyrosine ligase, which specifically lowers 
tubulin detyrosination. The positive effect of parthenolide 
on cardiomyocyte function of MYBPC32373insG cardiomyo-
cytes is, therefore, explained by a decrease in cardiomyo-
cyte stiffness due to lower levels of detyrosinated tubulin.
Overall, our findings in a European patient with HCM 
cohort strengthens the evidence that increased dety-
rosination of microtubules contributes to cardiomyocyte 
stiffness and dysfunction in HCM. Importantly, we show 
that this is especially true in the presence of a sarco-
mere mutation.
Study Limitations and Clinical Implications
We sex- and age-matched our experimental groups as 
good as the availability of human samples allowed us. As 
seen in the Table, sex and age, as well as most clinical 
parameters, are not statistically different between groups. 
We cannot exclude that differences in disease progres-
sion, as displayed by the difference in IVS thickness, E/e′ 
ratio and LVOTg between HCMSMP and HCMSMN, may 
influence the results. However, collection of patient heart 
tissue is only possible at the time of myectomy. There-
fore, all our samples have the same clinical end point, 
that is, time of myectomy. This is likely the cause for the 
low number of genotype-specific protein changes and 
we cannot exclude that genotype-specific differences 
might have occurred at earlier disease stages. Due to 
unavailability of myocardial biopsies from asymptomatic 
mutation carriers, animal models, and human-derived 
cardiomyocyte muscle models should provide insight into 
gene-specific pathomechanisms at early disease stages.
Most of the patients in this study have been on drug 
therapy, therefore, we cannot exclude that some of the 
proteomic changes are caused by medication. However, 
some of the main findings, for example, energy deficiency, 
have also been observed in animal models,39 and the 
number of patients on the most commonly used drugs 
does not differ between HCMSMP and HCMSMN (Table). 
Therefore, it is more likely that the observed changes are 
driven by disease rather than medication.
Although we detected and quantified a large number 
of proteins in this study, we do not reach full coverage 
of the proteome as this method only reliably quanti-
fies the more abundant proteins. Therefore, our list of 
differentially expressed proteins is not comprehensive. 
Also, we did not assess post-translational modifications 
in the proteomics study which have important regula-
tory functions. The changes at the protein level reflect 
whole tissue alterations and cannot be solely assigned 
to the mutation-carrying cardiomyocytes but might also 
arise from other cell types. However, cardiomyocytes are 
responsible for most of the tissue volume and, therefore, 
drive most of the protein changes.
Homozygous MYBPC32373insG mice do not fully 
resemble human HCM patients since patients typically 
carry heterozygous mutations. While both patients and 
the homozygous MYBPC32373insG mouse model show 
hypertrophy and diastolic dysfunction, the prominent 
LV systolic dysfunction as observed in the homozygous 
MYBPC32373insG mice is not seen in most patients with 
HCM. But due to the lack of phenotype in heterozygous 
mice they provide a suitable genetic model of loss of 
MYBPC3 protein levels.
In our proteomic screen in a large set of human HCM 
samples, we identified reduced levels of proteins involved 
in metabolic pathways as the most prominent derail-
ment. This finding supports recent and ongoing clinical 
trials investigating the therapeutic effect of targeting 
the metabolism in HCM. Based on the proteomic data 
and functional studies in a novel HCM mouse model, 
we propose that an increase in detyrosinated tubulin 
contributes to the clinical and cellular differences that 
we see between HCMSMP and HCMSMN samples (Fig-
ure 7). Detyrosinated microtubules may represent a tar-
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because reducing detyrosination improves contractile 
function in isolated cardiomyocytes. Since the increase in 
detyrosinated tubulin is largest in HCMSMP, this treatment 
strategy is proposed to be most beneficial in mutation-
positive HCM patients. A specific inhibitor of detyrosina-
tion needs to be developed due to the known off-target 
effects of parthenolide. As sarcomere mutation carriers 
are identified before disease onset, targeting the micro-
tubules may represent a preventive treatment option.
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